Sponsor pipeline

Matthew Galsky clinical trial pipeline

Get alerts when Matthew Galsky's trials change

2 active trials 1 recruiting 1 disease areas 2 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-08-06
Primary endpoint(s) modified
Enrollment increased: 47 → 75 participants
NCT06809140 Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of… · Phase 2

Active trials by phase

Phase 2
2

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2
NCT06809140 Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of… Muscle Invasive Bladder Urothelial Carcinoma Recruiting 2026-08-05
NCT05406713 Pembrolizumab in Muscle-invasive Bladder Cancer Muscle Invasive Bladder Carcinoma Active, Not Recruiting 2026-04-08

Disease areas by active trials

Bladder Cancer (2)

Get alerts when Matthew Galsky's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free